Quality and Experience Bring Value to Genetic Testing

Aaron Elliott, PhD
July 13th, 2018

Ambry was founded with one goal– help patients and families. It is with this goal in mind that we design every test, accession every sample, interpret every result, and generate every report. Prior to becoming CEO at Ambry, I held various positions here, including Chief Scientific Officer for 5 years. Our motto is to design, validate and perform every test as if one day your child will depend on the results. It is this culture we embrace at Ambry where we don’t cut corners or sacrifice quality for anything.

We have entered a new era of genetics where our knowledge about hereditary disease is rapidly increasing, the clinical utility of genetic testing is becoming more apparent, and more healthcare providers are commonly using genetic testing to guide patient care. We have seen endless testing options become clinically available, and the cost of testing has become a primary decision making factor for some. But with so many other factors to consider, how should you really choose which testing to use for your patients?

When it comes to confirming a diagnosis, guiding treatment, or making a plan for early detection and prevention of disease, genetic testing can provide valuable information. Healthcare decisions based on these results can be drastic and extremely expensive. Therefore, it is important to consider not only the cost of testing but the value of quality testing and experience. We have been in the business of rare disease testing for nearly 20 years and in that time have tested over a million patients and counting. We know it takes this kind of experience to be able to consistently deliver accuracy and clarity to patients and families. This is where the true value of genetic testing lies.

At Ambry, we understand that a one-time genetic test can have lifelong implications for your patients and their family members, so our team is focused on:

Finding answers through best-in-class variant interpretation
Confidently guiding patient care through reliable results
Understanding human disease through innovation, research, and partnerships

Over the next few months, we will be sharing with you details about Ambry’s dedication to quality, so that you can see the difference that we can make for you and your patients. Look for more details about the value of our enhanced variant interpretation, our expert variant team, and Ambry’s Translational Genomics (ATG) lab.

We look forward to continuing to be your trusted partner to deliver clear and accurate results to patients and families.

Find Answers & Improve Patient Care

Ambry is committed to delivering the most accurate genetic test results possible. Learn more about our products today.

Contact A Sales Rep

Love this article?

Get stories just like it, delivered right to your inbox.

Author

Aaron Elliott, PhD

Dr. Elliott joined Ambry Genetics in 2008 in the research and development department working closely on the development of comprehensive molecular diagnostic tests. An innovator in complex genetic testing, Dr. Elliott has been involved in the conception and implementation of many of the diagnostic industry first to market tests and technologies including the first commercial NGS assay, CLIA/CAP Exome test and hereditary cancer panels among others. Dr. Elliott and the Ambry team were instrumental in mounting a creative defense in the groundbreaking University of Utah Research Foundation, et al., v. Ambry Genetics Corporation case which ended the monopoly of BRCA testing in the United States.

Dr. Elliott has helped guide the company through extreme periods of growth, including the recent acquisition by Konica Minolta. Over the years he has held many leadership positions at Ambry, including Director of Genomic Services, Chief Operating Officer and Chief Scientific Officer.

Dr. Elliott began his career as a Postdoctoral Fellow at the Novartis Institute of Functional Genomics in San Diego, where he conducted research on potential drug targets for chemotherapeutic resistance and tumor formation. As part of this research, Dr. Elliott helped in identifying the first mitochondrial ABC transporter in cancer cells, which are responsible for multi-drug resistance in many solid tumors.

A graduate of Franklin and Marshall College, Dr. Elliott conducted his Ph.D. Genetics training at Thomas Jefferson University and The Johns Hopkins University School of Medicine.

DISCLAIMER: THIS BLOG DOES NOT PROVIDE MEDICAL ADVICE

The information, including but not limited to, text, graphics, images and other material contained on this blog are for informational purposes only. The purpose of this blog is to promote broad understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this blog. Ambry Genetics Corporation does not recommend or endorse any specific tests, physicians, products, procedures, opinions or other information that may be mentioned on this blog. Reliance on any information appearing on this blog is solely at your own risk.